Adoracion Pegalajar‐Jurado

Centers for Disease Control and Prevention

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Melissa M. Reynolds

Colorado State University

Ellen R. Fisher

Colorado State University

Morgan J. Hawker

California State University, Fresno

Bella H. Neufeld

Teknova

Claudia R. Molins

Centers for Disease Control and Prevention

Mark J. Delorey

Centers for Disease Control and Prevention

Jessica M. Joslin

Colorado State University

Laura V. Ashton

Colorado State University

M. Nurul Islam

Colorado State University

John T. Belisle

Colorado State University

Cooperative Institutions

Colorado State University

Centers for Disease Control and Prevention

National Center for Emerging and Zoonotic Infectious Diseases

Collins College

Johns Hopkins University

University of Utah

Vector (United States)

National Institutes of Health

Johns Hopkins Medicine

University of Baltimore

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Hydrophilic Modification of Polysulfone Ultrafiltration Membranes by Low Temperature Water Vapor Plasma Treatment to Enhance Performance

Plasma Processes and Polymers (2015)

Adoracion Pegalajar‐Jurado Michelle N. Mann Matthew R. Maynard Ellen R. Fisher

Porous polymeric membranes are used in numerous applications including water filtration systems. Fouling from proteins, toxins, bacteria, and cells present in the water limits membrane utility. Surface modification techniques that retain desired bulk properties while decreasing fouling can effectively extend membrane lifetime. Herein, water vapor plasmas are utilized to create hydrophilic polysulfone ultrafiltration membranes. The permanency of the treatment over two months correlates to covalent incorporation of hydrophilic functional groups into the polymer backbone. Modified membranes show enhanced hydrodynamic characteristics and do not require preconditioning. Thus, water vapor plasma modification provides a potential route to extend ultrafiltration membrane lifetime.

Polysulfone

Ultrafiltration (renal)

Filtration (mathematics)

Surface Modification

Membrane Fouling

10.1002/ppap.201500121

Cite

Citations (35)

Metabolic differentiation of early Lyme disease from southern tick–associated rash illness (STARI)

Science Translational Medicine (2017)

Claudia R. Molins Laura V. Ashton Gary P. Wormser Barbara André Ann M. Hess

Metabolic profiling provides a biochemical signature to objectively differentiate two illnesses with nearly identical clinical presentations, early Lyme disease and STARI.

10.1126/scitranslmed.aal2717

Cite

Citations (38)

Utilizing plasma processing to fabricate customizable three-dimensional, porous polymeric constructs: tuning substrate interactions with mammalian and bacterial cells

Frontiers in Bioengineering and Biotechnology (2016)

Hawker Morgan Mann Michelle Adoracion Pegalajar‐Jurado Fisher Ellen

Event Abstract Back to Event No Records Found Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Google Google Scholar PubMed Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

10.3389/conf.fbioe.2016.01.00121

Cite

Citations (0)

Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Laboratory Diagnosis Using Well-Characterized Serum Samples

Journal of Clinical Microbiology (2018)

Adoracion Pegalajar‐Jurado Martin E. Schriefer Ryan J. Welch Marc Roger Couturier Tiffany MacKenzie

Standard two-tiered testing (STTT) is the recommended algorithm for laboratory diagnosis of Lyme disease (LD). Several limitations are associated with STTT that include low sensitivity in the early stages of disease, as well as technical complexity and subjectivity associated with second-tier immunoblotting; therefore, modified two-tiered testing (MTTT) algorithms that utilize two sequential first-tier tests and eliminate immunoblotting have been evaluated. Recently, a novel MTTT that uses a VlsE chemiluminescence immunoassay followed by a C6 enzyme immunoassay has been proposed. The purpose of this study was to evaluate the performance of the VlsE/C6 MTTT using well-characterized serum samples. Serum samples from the CDC Lyme Serum Repository were tested using three MTTTs, VlsE/C6, whole-cell sonicate (WCS)/C6, and WCS/VlsE, and three STTTs (immunoblotting preceded by three different first-tier assays: VlsE, C6, and WCS). Significant differences were not observed between the results of the MTTTs assessed; however, the VlsE/C6 MTTT resulted in the highest specificity (100%) when other diseases were tested and the lowest sensitivity (75%) for LD samples. Significant differences were present between the results for various MTTTs and STTTs evaluated. Specifically, all MTTTs resulted in higher sensitivities than the STTTs for all LD groups combined and were significantly more accurate (i.e., higher proportion of correct classifications) for this group, with the exception of the WCS/ViraStripe STTT. Additionally, when other diseases were tested, only the results of the VlsE/C6 MTTT differed significantly from those of the WCS/ViraStripe STTT, with the VlsE/C6 MTTT resulting in a 6.2% higher accuracy. Overall, the VlsE/C6 MTTT offers an additional laboratory testing algorithm for LD with equivalent or enhanced performance compared to that of the other MTTTs and STTTs evaluated in this study.

10.1128/jcm.01943-17

Cite

Citations (82)

Allylamine and Allyl Alcohol Plasma Copolymerization: Synthesis of Customizable Biologically‐Reactive Three‐Dimensional Scaffolds

Plasma Processes and Polymers (2015)

Morgan J. Hawker Adoracion Pegalajar‐Jurado Kiah I. Hicks Jeffrey C. Shearer Ellen R. Fisher

Plasma copolymerization is a powerful plasma‐enhanced chemical vapor deposition (PECVD)‐based technique, and offers a distinct advantage over single‐precursor PECVD of being able to deposit films with tunable functionality by adjusting the plasma precursor ratio. Here, an allylamine/allyl alcohol plasma copolymerization system was used to modify two‐dimensional (2D) and three‐dimensional (3D) substrates for biomedical applications. Films with customizable and predictable nitrogen and oxygen content, as well as surface wettability, were deposited on both Si wafers and 3D polymer scaffolds across a range of copolymerization conditions. Additionally, the bioreactivity of plasma‐modified materials was evaluated using both human dermal fibroblast and E coli attachment studies.

Allylamine

Allyl alcohol

Vinyl alcohol

Plasma polymerization

Plasma activation

10.1002/ppap.201500098

Cite

Citations (8)

Metabolic Response in Patients With Post-treatment Lyme Disease Symptoms/Syndrome

Clinical Infectious Diseases (2020)

Bryna L. Fitzgerald Barbara Graham Mark J. Delorey Adoracion Pegalajar‐Jurado M. Nurul Islam

Post-treatment Lyme disease symptoms/syndrome (PTLDS) occurs in approximately 10% of patients with Lyme disease following antibiotic treatment. Biomarkers or specific clinical symptoms to identify patients with PTLDS do not currently exist and the PTLDS classification is based on the report of persistent, subjective symptoms for ≥6 months following antibiotic treatment for Lyme disease.Untargeted liquid chromatography-mass spectrometry metabolomics was used to determine longitudinal metabolic responses and biosignatures in PTLDS and clinically cured non-PTLDS Lyme patients. Evaluation of biosignatures included (1) defining altered classes of metabolites, (2) elastic net regularization to define metabolites that most strongly defined PTLDS and non-PTLDS patients at different time points, (3) changes in the longitudinal abundance of metabolites, and (4) linear discriminant analysis to evaluate robustness in a second patient cohort.This study determined that observable metabolic differences exist between PTLDS and non-PTLDS patients at multiple time points. The metabolites with differential abundance included those from glycerophospholipid, bile acid, and acylcarnitine metabolism. Distinct longitudinal patterns of metabolite abundance indicated a greater metabolic variability in PTLDS versus non-PTLDS patients. Small numbers of metabolites (6 to 40) could be used to define PTLDS versus non-PTLDS patients at defined time points, and the findings were validated in a second cohort of PTLDS and non-PTLDS patients.These data provide evidence that an objective metabolite-based measurement can distinguish patients with PTLDS and help understand the underlying biochemistry of PTLDS.

10.1093/cid/ciaa1455

Cite

Citations (17)

Biodegradable citrate-based polyesters with S-nitrosothiol functional groups for nitric oxide release

Journal of Materials Chemistry B (2015)

Janet P. Yapor Alec Lutzke Adoracion Pegalajar‐Jurado Bella H. Neufeld Vinod B. Damodaran

Nitric oxide (NO) is a biologically-active free radical involved in numerous physiological processes such as regulation of vasodilation, promotion of cell proliferation and angiogenesis, and modulation of the inflammatory and immune responses. Furthermore, NO has demonstrated the ability to mitigate the foreign body response that often results in the failure of implanted biomedical devices. Although NO has promising therapeutic value, the short physiological half-life of exogenous NO complicates its effective delivery. For this reason, the development of NO-releasing materials that permit the localized delivery of NO is an advantageous method of utilizing this molecule for biomedical applications. Herein, we report the synthesis and characterization of biodegradable NO-releasing polyesters prepared from citric acid, maleic acid, and 1,8-octanediol. NO release was achieved by incorporation of S-nitrosothiol donor groups through conjugation of cysteamine and ethyl cysteinate to the polyesters, followed by S-nitrosation with tert-butyl nitrite. The extent of NO loading and the release properties under physiological conditions (pH 7.4 PBS, 37 °C) were determined by chemiluminesence-based NO detection. The average total NO content of poly(citric-co-maleic acid-co-1,8-octanediol)-cysteamine was determined to be 0.45 ± 0.07 mol NO g-1 polymer, while the NO content for poly(citric-co-maleic acid-co-1,8-octanediol)-ethyl cysteinate was 0.16 ± 0.04 mol NO g-1 polymer. Continuous NO release under physiological conditions was observed for at least 6 days for the cysteamine analog and 4 days for the ethyl cysteinate analog. Cell viability assays and morphological studies with human dermal fibroblasts indicated an absence of toxic leachates at a cytotoxic level, and suggested that these citrate-based polyesters may be suitable for future biomedical applications.

Nitric acid

10.1039/c5tb01625h

Cite

Citations (16)

Innovative Applications of Surface Wettability Measurements for Plasma‐Modified Three‐Dimensional Porous Polymeric Materials: A Review

Plasma Processes and Polymers (2015)

Morgan J. Hawker Adoracion Pegalajar‐Jurado Ellen R. Fisher

This review addresses state‐of‐the‐art of wettability measurements for plasma‐modified, three‐dimensional (3D), porous, polymeric materials. Inherent challenges associated with evaluating wettability of these complex constructs are discussed, including expanding techniques from 2D to 3D substrates and collection of both static and dynamic contact angle (CA) data. Dynamic data include advancing and receding CA measurements, as well as changes in CA as a function of time. Limitations in analysis and interpretation of wettability data are highlighted to best represent wetting characteristics of plasma‐treated porous materials, as is the importance of placing wettability data in context with simultaneous surface chemistry and roughness assessment. A list of best practices recommendations is provided.

10.1002/ppap.201500035

Cite

Citations (20)

Abstract TMIM-082: OVACURE - BRINGING PERSONALIZED TREATMENT TO WOMEN WITH OVARIAN CANCER

Clinical Cancer Research (2019)

Adoracion Pegalajar‐Jurado

Abstract Immunotherapy has revolutionized the treatment of many types of cancer and is now undergoing testing in ovarian cancer (OC). Several immunotherapeutic approaches are currently being developed for OC treatment; including tumor infiltrating lymphocytes based adoptive cell therapy (TIL based ACT), chimeric antigen receptor–modified T-cells (CAR T-cell), personalized vaccines and immune checkpoint blockade. Additionally, the importance of using combination of therapies and obtaining information on different group of patients (treatment responsive and unresponsive) prior to designing new approaches, has been widely identified. Although being able to choose a more targeted combination therapy can potentially be lifesaving for OC patients; identifying the successful treatment combination is challenging due to the low mutation frequency in this cancer and the variability observed patient to patient. Our goal is to support OC patients from a synergetic point of view. OvaCure portfolio contributes to almost all the immunotherapeutic approaches mentioned above; as well as to understanding how patients respond to different treatment combinations and how this information can be used to improve patient care. OvaCure's T-cell Immune Therapy Branch consist in three parallel trials that build in and complement each other, and that aim to make a meaningful impact by moving forward TIL based ACT. Our first clinical trial is led by Prof. Svane - Denmark, and has already contributed to state-of-the-art of stablishing the medical plausibility of treating recurrent OC with TIL based ACT. The clinical Phase I/II - Immunotherapy by adoptive T-cell infusion in the event of advanced ovarian cancer (stage III/IV), will be completed in 2019 and will provide an overview of the clinical efficacy of TIL based ACT in combination with anti-CTLA-4 antibody Ipilimumab and PD-1 antibody. The second trial, clinical Phase I - Combined chemo- and adoptive T-cell therapy (ACT) as treatment for recurrent epithelial ovarian carcinoma, is led by Ass. Prof. Verdegaal - The Netherlands. Patient enrolment commenced early 2018, and the trial will provide insight on the role of interferon alfa in enhancement of T-cell survival, improvement of TILs persistence and effectiveness, and in lowering toxicity for patients. The third project in our T-cell Immune Therapy Branch is led by Prof. Coukos – Switzerland, and aims to identify the human tumour cells expressed antigenic determinants. The coming Clinical Phase I will assess the clinical efficacy of utilizing the selected tumor-specific T-cells against OC. Tumour-match: Combination of immune therapy with a next generation patient selection platform to improve treatment outcomes is also part of our portfolio. Herein, Dr. Mirza combines two breakthroughs in cancer: immune therapy with a next generation patient selection platform using RNA sequencing. This study strives to develop gene expression signatures that could guide treatment decisions, can be used to monitor disease progression and open the window to diagnostic opportunities. OvaCure's core focus is to make a positive impression on society by supporting experimental, bold and risk-taking research; as well as, promoting awareness through public outreach. Visit our website (www.ovacure.org) for more information about our research and activities. Citation Format: Adoracion Pegalajar-Jurado. OVACURE - BRINGING PERSONALIZED TREATMENT TO WOMEN WITH OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr TMIM-082.

10.1158/1557-3265.ovcasymp18-tmim-082

Cite

Citations (0)

Reprint of: Nitric oxide-releasing polysaccharide derivative exhibits 8-log reduction against Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus

Journal of Controlled Release (2015)

Adoracion Pegalajar‐Jurado Kathryn A. Wold Jessica M. Joslin Bella H. Neufeld Kristin A. Arabea

Acinetobacter baumannii

Bacterial growth

Multidrug tolerance

10.1016/j.jconrel.2015.11.024

Cite

Citations (14)